Continuous High-Dose Intravenous Vitamin C:
An Early Safety Study in Patients with Advanced Cancer
High-dose intravenous vitamin C (intravenous ascorbate) differs from routine oral vitamin supplementation because intravenous administration can raise blood ascorbate concentrations substantially.
In patients with advanced cancer, one important question in early clinical research was whether sustained administration of higher-dose intravenous ascorbate could be tolerated and what safety issues might emerge.
What Did the Study Do?
The study enrolled 24 patients with advanced cancer and administered ascorbate by continuous intravenous infusion, primarily evaluating safety, tolerability, and clinical feasibility.
24
A Single-Arm Pilot Study Focused on Safety
Patients received continuous intravenous ascorbate. During the study, blood chemistry, blood counts, and plasma ascorbate concentrations were monitored regularly.
Investigators also recorded general clinical status, adverse events, and disease progression. The primary purpose was not to formally establish antitumour efficacy.
Continuous intravenous ascorbate was administered using weight-based dosing.
150–710 mg/kg/day
The main study infusion period could continue for approximately eight weeks.
Up to ~8 Weeks
Blood chemistry and haematological parameters were monitored at approximately weekly intervals.
Approximately Weekly
How Did Plasma Ascorbate Concentrations Change During Continuous Infusion?
Before the study, most patients had relatively low vitamin C levels. Continuous intravenous infusion substantially increased plasma ascorbate concentrations.
What Adverse Events Were Observed?
More commonly reported adverse effects included nausea, oedema, and dry mouth or dry skin. Most were relatively mild.
Nausea was among the more commonly reported adverse effects, with most events being mild.
Nausea
Some patients developed oedema, and overall clinical status was monitored throughout the study.
Oedema
Dry mouth or dry skin was also among the more commonly recorded mild adverse effects.
Dry Mouth or Dry Skin
The Study Also Recorded Two Grade 3 Events Considered Possibly Related to the Intervention
Kidney Stone
One patient with a pre-existing history of kidney stones developed another stone after approximately 13 days of continuous infusion. This event highlights why a previous history of urinary stone disease is an important risk factor when considering high-dose intravenous vitamin C.
Hypokalaemia
Another patient developed hypokalaemia after approximately six weeks of infusion. Electrolyte status therefore represents another area that may require monitoring according to individual circumstances.
Grade 3 · Around Week 6
Did the Study Establish Tumour-Control Effects?
1
The Study Did Not Establish Objective Antitumour Efficacy
Only one patient experienced stable disease and continued receiving the intervention beyond the main study period for a longer duration. This individual finding cannot establish that continuous high-dose intravenous vitamin C controls advanced cancer.
How Should This Study Be Interpreted?
This was a single-arm pilot study involving only 24 patients, with no randomisation and no control group. Its main value therefore lies in providing early human safety data.
Early Safety Data Should Not Be Interpreted as Established Cancer Efficacy
The study suggests that continuous intravenous ascorbate may be feasible in some appropriately selected and monitored patients. It does not answer whether high-dose vitamin C can shrink tumours, delay disease progression, or prolong survival.
Nausea, oedema, and dry mouth or dry skin were among the more commonly reported events, with most being relatively mild.
Most Adverse Events Were Mild
The kidney stone and hypokalaemia events underline the importance of renal, stone-related, and electrolyte risk assessment.
Individual Risk Factors Remain Important
The single-arm design, small sample, and advanced disease status limit any conclusions about tumour control or survival.
Cancer Efficacy Cannot Be Determined
Which Risk Factors Require Particular Attention?
Current clinical evidence suggests that high-dose intravenous vitamin C should be considered with appropriate medical assessment and monitoring, particularly when individual risk factors may increase the likelihood of complications.
How Does BMS Clinic View This Evidence?
This study reinforces that high-dose intravenous vitamin C is not equivalent to routine daily nutritional supplementation. It is an intravenous medical intervention that requires appropriate assessment and monitoring.
Before considering this type of medical support, relevant factors include renal function, previous kidney or urinary stone history, G6PD status, electrolyte levels, cancer status, current cancer-care arrangements, and other individual health risks.
BMS Clinic emphasises professional assessment based on current medical evidence and individual health circumstances. Early safety studies can help clarify potential risks and clinical feasibility, but should not be interpreted as established evidence of cancer efficacy.
This article is provided for medical education and literature reference only. It does not replace diagnosis, assessment, or personalized medical advice from a qualified healthcare professional.
This was a small, single-arm pilot clinical study primarily evaluating the safety and tolerability of high-dose intravenous ascorbate. Kidney stones and hypokalemia were among the adverse events reported, and the findings do not establish that high-dose vitamin C can control cancer, shrink tumors, or prolong survival.
Patients with cancer considering this form of supportive medical care should undergo professional assessment based on their individual condition, kidney function, history of kidney stones, G6PD status, and current medical care.
Learn More About the Safety Assessment of High-Dose Intravenous Vitamin C
This early study primarily provides safety and tolerability data on continuous high-dose intravenous vitamin C, while highlighting the importance of kidney stone risk, electrolyte abnormalities, and other individual risk factors. The findings do not establish a confirmed cancer-control benefit. Anyone considering this type of medical support should first undergo professional assessment of kidney function, G6PD status, kidney stone history, electrolyte levels, and their current cancer care.